Cemento-ossifying fibroma on the mandible: a case report

Cemento-ossifying fibroma is a benign fibro-osseous neoplasm that appears on the craniofacial region. A 43-year-old female patient was referred to the oral and maxillofacial pathology service of a university due to a mandible lesion. The clinical examination showed a bony hard swelling on the buccal cortical within the second premolar and first molar on the left side of the mandible. The patient denied pain or numbness. The panoramic x-ray showed a unilocular lesion with well-defined borders. The clinical diagnosis was an odontogenic keratocyst. An exploratory punction was performed, with a yellow fluid being collected from the lesion. An incisional biopsy was made, and the histopathology showed a benign neoplastic lesion comprised of the proliferation of spindle cells, resembling fibroblasts, as well as calcified matrix material resembling both bone and cementoid material. The final diagnosis was cemento-ossifying fibroma. The patient underwent surgery and is now under a 6-month follow-up without recurrence. Cemento-ossifying fibroma is a benign fibro-osseous neoplasm that appears on the craniofacial region. A 43-year-old female patient was referred to the oral and maxillofacial pathology service of a university due to a mandible lesion. The clinical examination showed a bony hard swelling on the buccal cortical within the second premolar and first molar on the left side of the mandible. The patient denied pain or numbness. The panoramic x-ray showed a unilocular lesion with well-defined borders. The clinical diagnosis was an odontogenic keratocyst. An exploratory punction was performed, with a yellow fluid being collected from the lesion. An incisional biopsy was made, and the histopathology showed a benign neoplastic lesion comprised of the proliferation of spindle cells, resembling fibroblasts, as well as calcified matrix material resembling both bone and cementoid material. The final diagnosis was cemento-ossifying fibroma. The patient underwent surgery and is now under a 6-month follow-up without recurrence.